Home / Health / Gene Edit Offers Single Shot to Lower Bad Cholesterol
Gene Edit Offers Single Shot to Lower Bad Cholesterol
27 May
Summary
- Single infusion therapy VERVE-102 reduced LDL by 62%.
- The therapy permanently switches off the PCSK9 gene.
- Early trials show 18-month persistent cholesterol reduction.
A novel gene-editing therapy, VERVE-102, is challenging the long-held view of high cholesterol as a lifelong condition. Developed by Eli Lilly and Verve Therapeutics, a single infusion of this experimental treatment has shown the potential to drastically reduce low-density lipoprotein (LDL) cholesterol.
In an early-stage clinical trial published in 'The New England Journal of Medicine', VERVE-102 lowered LDL cholesterol by 62% and PCSK9 protein levels by 88% in participants. These significant reductions persisted for at least 18 months after the single intravenous treatment, with the therapy generally well-tolerated and no serious adverse events reported.
VERVE-102 works by permanently deactivating the PCSK9 gene in the liver, which is responsible for destroying LDL cholesterol receptors. This approach mimics a natural genetic variation that confers lifelong protection against heart disease. If larger trials confirm these findings, it could herald a new era in preventive cardiology, offering a one-time genetic intervention.
The implications are particularly significant for India, where heart disease affects younger populations. While promising, experts emphasize the need for further large-scale trials to confirm long-term cardiovascular benefits and assess scalability and affordability. This marks a crucial proof of concept for genetic intervention in cholesterol management.
